Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities and Strategies to 2034

This report describes and explains the non-small cell lung cancer (NSCLC) market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global non-small cell lung cancer (NSCLC) market reached a value of nearly $38.19 billion in 2024, having grown at a compound annual growth rate (CAGR) of 7.68% since 2019. The market is expected to grow from $38.19 billion in 2024 to $63.7 billion in 2029 at a rate of 10.77%. The market is then expected to grow at a CAGR of 10.55% from 2029 and reach $105.2 billion in 2034.

Growth in the historic period resulted from growing demand for precision medicine, rising prevalence of smoking and air pollution, expansion of clinical trials and rising prevalence of lung cancer. Factors that negatively affected growth in the historic period were high treatment costs and adverse effects of chemotherapy.

Going forward, increasing research and development in healthcare, rise in public awareness campaigns, rise in advancements in targeted therapies and immunotherapies and growing demand for precision medicine will drive growth. Factors that could hinder the growth of the non-small cell lung cancer (NSCLC) market in the future include limited stringent regulatory approvals, impact of trade war and tariffs and limited access in developing regions competition from substitute products and impact of trade war and tariff.

North America was the largest region in the non-small cell lung cancer (NSCLC) market, accounting for 43.66% or $16.67 billion of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the non-small cell lung cancer (NSCLC) market will be Asia-Pacific and Africa where growth will be at CAGRs of 12.49% and 12.02% respectively. These will be followed by Middle East and Eastern Europe where the markets are expected to grow at CAGRs of 11.64% and 10.43% respectively.

The global non-small cell lung cancer (NSCLC) market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 76.71% of the total market in 2024. Merck & Co., Inc. was the largest competitor with a 23.15% share of the market, followed by AstraZeneca with 22.57%, Bristol-Myers Squibb Company with 13.15%, F. Hoffmann-La Roche AG, with 11.11%, Pfizer Inc., with 2.07%, Eli Lilly and Company with 1.50%, Regeneron Pharmaceuticals Inc. with 1.27%, Amgen Inc. with 0.69%, Novartis AG with 0.65% and Takeda Pharmaceutical Company Limited with 0.55%.

The non-small cell lung cancer (NSCLC) market is segmented by type into squamous cell carcinoma, large cell carcinoma, adenocarcinoma and other types. The adenocarcinoma market was the largest segment of the non-small cell lung cancer (NSCLC) market segmented by type, accounting for 44.04% or $16.82 billion of the total in 2024. Going forward, the adenocarcinoma segment is expected to be the fastest growing segment in the non-small cell lung cancer (NSCLC) market segmented by type, at a CAGR of 13.68% during 2024-2029.

The non-small cell lung cancer (NSCLC) market is segmented by therapy into radiation therapy, chemotherapy, targeted therapy, immunotherapy and other therapies. The chemotherapy market was the largest segment of the non-small cell lung cancer (NSCLC) market segmented by therapy, accounting for 30.92% or $11.81 billion of the total in 2024. Going forward, the immunotherapy segment is expected to be the fastest growing segment in the non-small cell lung cancer (NSCLC) market segmented by therapy, at a CAGR of 20.66% during 2024-2029.

The non-small cell lung cancer (NSCLC) market is segmented by distribution channel into hospital pharmacy, online pharmacy and other distribution channels. The hospital pharmacy market was the largest segment of the non-small cell lung cancer (NSCLC) market segmented by distribution channel, accounting for 69.17% or $26.42 billion of the total in 2024. Going forward, the online pharmacy segment is expected to be the fastest growing segment in the non-small cell lung cancer (NSCLC) market segmented by distribution channel, at a CAGR of 18.64% during 2024-2029.

The top opportunities in the non-small cell lung cancer (NSCLC) market segmented by type will arise in the adenocarcinoma segment, which will gain $15.11 billion of global annual sales by 2029. The top opportunities in the non-small cell lung cancer (NSCLC) market segmented by therapy will arise in the immunotherapy segment, which will gain $12.02 billion of global annual sales by 2029. The top opportunities in the non-small cell lung cancer (NSCLC) market segmented by distribution channel will arise in the hospital pharmacy segment, which will gain $17.58 billion of global annual sales by 2029. The non-small cell lung cancer (NSCLC) market size will gain the most in the USA at $9.42 billion.

Market-trend-based strategies for the non-small cell lung cancer (NSCLC) market include bromodomain inhibitor gains fast track designations for resistant non-small cell lung cancer, dual-immune activation therapy shows promise in immunotherapy-resistant NSCLC, rapid 24-hour tumor profiling for precision NSCLC treatment, oral tyrosine kinase inhibitors accelerate targeted NSCLC treatment advances, FDA clears investigational mRNA-based precision immunotherapy.

Player-adopted strategies in the non-small cell lung cancer (NSCLC) market include focus on expanding its business capabilities through strategic partnerships.

To take advantage of the opportunities, the analyst recommends the non-small cell lung cancer (NSCLC) companies to focus on integrating augmented reality for enhanced driver experience and safety, focus on advancing dual-immune activation to address therapy resistance in nsclc, focus on accelerating diagnostic solutions to improve treatment timeliness in nsclc, focus on developing oral tyrosine kinase inhibitors to enhance targeted nsclc treatment, focus on advancing mrna-based precision immunotherapy for personalized nsclc treatment, focus on advancing third-generation egfr-tkis to address drug resistance in nsclc, focus on expanding presence in the adenocarcinoma segment to capture high-growth opportunities, focus on expanding in the immunotherapy segment to drive market growth, expand in emerging markets, continue to focus on developed markets, focus on expanding omnichannel distribution to improve market reach, focus on optimizing value-based pricing to enhance market competitiveness, focus on strengthening physician and patient engagement to increase treatment awareness, focus on expanding digital and data-driven marketing to improve reach and efficiency, focus on strengthening presence in the online pharmacy segment to maximize growth.